<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590277</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-026-11F</org_study_id>
    <nct_id>NCT01590277</nct_id>
  </id_info>
  <brief_title>Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans</brief_title>
  <official_title>Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is
      looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's
      effects on driving an automobile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol is abused commonly, but there is no antidote for alcohol intoxication the way
      naltrexone or naloxone is an antidote for opioids. A medication that has the potential to
      block alcohol actions in the Central Nervous System could act as a unique medication in the
      treatment of alcohol intoxication and alcoholism. This project is evaluating the
      benzodiazepine partial inverse agonist, iomazenil, as an agent that could reverse alcohol's
      effects on subjective intoxication, alcohol's effects on driving using a driving simulator
      and on measures of electrophysiology in the laboratory in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Automobile driving</measure>
    <time_frame>4 years</time_frame>
    <description>Driving stimulator</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Active Ethanol and Active Iomazenil</condition>
  <condition>Active Ethanol and Placebo Iomazenil</condition>
  <condition>Placebo Ethanol and Placebo Iomazenil</condition>
  <condition>Placebo Ethanol and Active Iomazenil</condition>
  <arm_group>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil</description>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_label>placebo iomazenil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iomazenil</intervention_name>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil</description>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_label>placebo iomazenil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males

          -  21-35 years old

          -  Medically healthy

        Exclusion Criteria:

          -  Under the age of 21 or greater than the age 35

          -  History of seizures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak D'Souza, MD MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CERC (VISN1, West Haven, CT)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

